Jazz Pharmaceuticals plc (JAZZ) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 48 analysts3.9% Below Target
JAZZ trades 3.9% below Wall Street's consensus target of $257.44.
Current Price$247.72
Average Target$257.44
Target
Current
Low$229.00
Median$252.00
High$307.00
Analyst Target Range
Forward P/E9.8x
(Value)
PEG Ratio—
Implied Growth+5584.8%
(High Growth)
Analyst Spread30.3%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes JAZZ achieves its forward estimates and maintains a stable P/E multiple of 9.8x. This scenario reflects the blended consensus of 48 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
JAZZ Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Jazz Pharmaceuticals plc (JAZZ) has a Wall Street consensus price target of $257.44, based on estimates from 48 covering analysts. With the stock currently trading at $247.72, this represents a potential upside of +3.9%. The company has a market capitalization of $15.54B.
Analyst price targets range from a low of $229.00 to a high of $307.00, representing a 30% spread in expectations. The median target of $252.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 43 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, JAZZ trades at a trailing P/E of -42.4x and forward P/E of 9.8x. Analysts expect EPS to grow +5584.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $108.05, with bear and bull scenarios of $68.07 and $142.37 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+39.0%
Industry Consensus
Avg Forward P/E
21.1x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SUPNSupernus Pharmaceuticals, Inc. | $2.7B | $47.41 | $65.00 | +37.1% | Buy | 19.1x | 14 |
 PCRXPacira BioSciences, Inc. | $1.0B | $25.82 | $32.00 | +23.9% | Hold | 9.0x | 36 |
 INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
 AVNSAvanos Medical, Inc. | $1.2B | $24.92 | $23.00 | -7.7% | Hold | 24.9x | 8 |
 PRGOPerrigo Company plc | $1.5B | $11.19 | $36.20 | +223.5% | Hold | 5.3x | 36 |
 ALKSAlkermes plc | $9.2B | $55.22 | $52.60 | -4.7% | Buy | — | 29 |
 INCYIncyte Corporation | $23.6B | $118.05 | $108.92 | -7.7% | Buy | 15.4x | 44 |
 HALOHalozyme Therapeutics, Inc. | $9.7B | $81.57 | $88.25 | +8.2% | Buy | 10.1x | 27 |
 ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
 AVPTAvePoint, Inc. | $2.7B | $12.51 | $15.00 | +19.9% | Buy | 31.0x | 12 |
JAZZ — Frequently Asked Questions
Quick answers to the most common questions about buying JAZZ stock.
What is the JAZZ stock price target for 2026?
The consensus price target for JAZZ is $257.44, close to the current price of $247.72 (3.9% implied move). Based on 48 analyst estimates, the stock appears fairly valued near current levels.
Is JAZZ a buy, sell, or hold?
JAZZ has a consensus rating of "Buy" based on 48 Wall Street analysts. The rating breakdown is predominantly bullish, with 43 Buy/Strong Buy ratings. The consensus 12-month price target of $257.44 implies 3.9% upside from current levels.
Is JAZZ stock overvalued or undervalued?
With a forward P/E of 9.7659x, JAZZ trades at a relatively low valuation. The consensus target of $257.44 implies 3.9% appreciation, suggesting the market may be pricing in risks.
How high can JAZZ stock go?
The most bullish Wall Street analyst has a price target of $307 for JAZZ, while the most conservative target is $229. The consensus of $257.44 represents the median expectation. Our quantitative valuation model projects a bull case target of $142 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover JAZZ stock?
JAZZ is heavily covered by Wall Street, with 48 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 43 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the JAZZ stock forecast?
The 12-month JAZZ stock forecast based on 48 Wall Street analysts shows a consensus price target of $257.44, with estimates ranging from $229 (bear case) to $307 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $108, with bear/bull scenarios of $68/$142.
What is JAZZ's fair value based on fundamentals?
Our quantitative valuation model calculates JAZZ's fair value at $108 (base case), with a bear case of $68 and bull case of $142. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
What is JAZZ's forward P/E ratio?
JAZZ trades at a forward P/E ratio of 9.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy JAZZ stock?
JAZZ appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $257.44 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do JAZZ price targets vary so much?
JAZZ analyst price targets range from $229 to $307, a 30% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $257.44 consensus represents the middle ground. Our model's $68-$142 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare